Matinas biopharma announces notification of nyse american continued listing deficiency

Bedminster, n.j., sept. 22, 2023 (globe newswire) -- matinas biopharma (nyse american: mtnb), a clinical-stage biopharmaceutical company focused on redefining the intracellular delivery of small molecules and small oligonucleotides with its lipid nanocrystal (lnc) platform technology, today announced that it has received a deficiency letter ("letter") from nyse american llc ("nyse american" or the "exchange") stating that the company is not in compliance with the continued listing standards as set forth in section 1003(f)(v) of the nyse american company guide ("company guide").
MTNB Ratings Summary
MTNB Quant Ranking